List view / Grid view
Research shows the complexity and number of biologics is increasing,…
Research shows the complexity and number of biologics is increasing, as is the frequency at which their active pharmaceutical ingredient (API) production is outsourced.
A new report shows half the drugs and all the…
A new report shows half the drugs and all the vaccines approved for emergency use in 2020 had an associated contract manufacturing agreement.
Reports have found that the COVID-19 pandemic is providing new…
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
Dose contract manufacturing organisations (CMOs) had slow revenue growth in…
Dose contract manufacturing organisations (CMOs) had slow revenue growth in 2019, a trend continuing into 2020 that could impact the US.
A new report has found that three quarters of dose…
A new report has found that three quarters of dose manufacturing facilities acquired by dedicated CMOs in 2019 were in Europe.
A report has said that with only 152 CMOs able…
A report has said that with only 152 CMOs able to manufacture the 7,000 cell and gene therapies in the pipeline, production bottlenecks may occur.
According to findings, the majority of CMOs in Italy are…
According to findings, the majority of CMOs in Italy are found in the locations hit worst by COVID-19, meaning the pharma supply chain has been greatly impacted.
A new report has found that in 2019 the FDA approved 119 new…
A new report has found that in 2019 the FDA approved 119 new drugs and biologics, but that this is down from 137 in 2018, impacting contract manufacturing organisations.
The dose CMO industry is performing strongly despite challenges of…
The dose CMO industry is performing strongly despite challenges of increasingly complex drug production, says a new report.
The market for containment facilities and containment manufacturing will increase…
The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
